HER2-targeted IgG1 monoclonal antibody that blocks ERBB2 signaling and mediates ADCC.
Humanized IgG1 monoclonal antibody targeting HER2/ERBB2; binds the receptor to inhibit HER2 signaling and receptor dimerization, promotes receptor downregulation, and elicits antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
Trastuzumab binds HER2 on tumor cells and engages FcγR-bearing effector cells (e.g., NK cells, macrophages) to mediate ADCC; it may also trigger complement-dependent cytotoxicity and can promote apoptosis via HER2 signaling blockade.
HER2-targeted antibody–drug conjugate (T-DM1) that delivers the maytansinoid microtubule inhibitor DM1.
HER2-targeted monoclonal antibody (trastuzumab) linked via a nonreducible thioether (MCC) to the maytansinoid DM1; after binding HER2 and internalization, DM1 is released intracellularly to bind tubulin and disrupt microtubule dynamics, inhibiting cell division and inducing cancer cell death. Trastuzumab also inhibits HER2 signaling and can mediate Fc-dependent immune effector functions.
ADC binds HER2, is internalized, and releases the DM1 payload that binds tubulin, disrupting microtubules and causing mitotic arrest and apoptosis; Fc effector functions (e.g., ADCC) may add killing.
HER2-targeted antibody–drug conjugate (T-DXd) that delivers deruxtecan, a topoisomerase I inhibitor with a membrane-permeable payload enabling bystander effect.
HER2-targeted antibody–drug conjugate: trastuzumab binds HER2 on tumor cells and can induce ADCC; upon internalization a cleavable linker releases deruxtecan (DXd), a membrane‑permeable topoisomerase I inhibitor, leading to DNA damage, replication arrest, apoptosis, and bystander killing of neighboring tumor cells.
ADC binds HER2 via trastuzumab, is internalized, and releases deruxtecan (DXd), a topoisomerase I inhibitor that causes DNA damage and apoptosis; Fc-mediated ADCC also contributes. Membrane-permeable payload enables bystander killing.
An intravenous, half-life extended bispecific T-cell engager (BiTE) that binds DLL3 on SCLC cells and CD3 on T cells to redirect cytotoxic T-cell killing of DLL3-positive tumor cells.
Half-life–extended bispecific T-cell engager that binds DLL3 on tumor cells and CD3 on T cells, activating and redirecting cytotoxic T cells to mediate lysis of DLL3-expressing tumor cells (e.g., SCLC).
Bispecific T-cell engager binds DLL3 on tumor cells and CD3 on T cells, creating an immune synapse that activates cytotoxic T cells to kill DLL3-positive cells via perforin/granzyme-mediated lysis.
A Trop-2-targeted antibody-drug conjugate that delivers SN-38 (irinotecan's active metabolite), a topoisomerase I inhibitor, causing DNA damage and tumor cell death with a potential bystander effect.
A Trop-2-targeted antibody-drug conjugate that binds Trop-2 on tumor cells, is internalized, and releases SN-38 (irinotecan's active metabolite). SN-38 inhibits topoisomerase I by stabilizing Topo I-DNA complexes, leading to DNA breaks, inhibition of replication, and apoptosis, with a potential bystander killing effect.
The ADC binds TROP-2 on tumor cells, is internalized, and releases SN-38, a topoisomerase I inhibitor, causing DNA damage and apoptosis (with potential bystander killing).